Tiziana Life Sciences (TLSA) announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists discontinuation. This advancement offers a promising approach to overcoming the tolerability challenges and adverse effects commonly linked to prolonged GLP-1 drug use. “These findings are a pivotal step forward in the treatment of metabolic disorders and age-related diseases,” added Tiziana’s CEO, Ivor Elrifi. “Nasal anti-CD3 provides a unique opportunity to maximize and sustain the therapeutic benefits of GLP-1 drugs while mitigating their associated risks, ensuring long-term health and improved outcomes for patients.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences’ Foralumab Shows Promise in Neurodegenerative Disease Treatment
- Tiziana Life Sciences announces review article on foralumab’s potential
- Tiziana Life Sciences Advances Alzheimer’s Treatment with Intranasal Foralumab
- Tiziana Life Sciences announces first patient dosed with intranasal foralumab
- Tiziana Life Sciences Expands MS Clinical Trial Network